Stockscreener 앱 받기
785.39
0.65%
5.86
Lilly Eli Co 주식(LLY)의 최신 뉴스
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug - Reuters
Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly - The Malaysian Reserve
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges in GLP-1 market - Investing.com
Eli Lilly genetic medicine acquisition to address cardiovascular risk - European Pharmaceutical Review
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in We - GuruFocus
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech - BioSpace
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - The Globe and Mail
Eli Lilly Stock Dips (18 Jun): Analyzing the Drop and What Traders Should Do Next - Daily Chhattisgarh News
UBS reiterates buy rating on Eli Lilly stock following Verve acquisition - Investing.com
Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal - Investing.com Canada
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug - rrdailyherald.com
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Eli Lilly to buy gene-editing biotech Verve for $1.3 billion - The Boston Globe
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News
Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN
UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business
Lilly to acquire Verve in $1B bet on gene editing for heart disease - BioPharma Dive
Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - Yahoo
Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit
Eli Lilly Expands Gene-Editing Arsenal With Verve Acquisition - Finimize
Lilly adds highest Zepbound doses to DTC offering - STAT
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN
Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg
Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters
Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint
Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News
Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com
Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24
Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News
Lilly spends $1B on Boston biotech developing gene-editing cholesterol drug - The Business Journals
Eli Lilly to acquire Verve Therapeutics for USD 1.3 billion - Medical Dialogues
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition - Benzinga
Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion - STAT
Eli Lilly (LLY) to Acquire Verve Therapeutics in $1.3 Billion De - GuruFocus
Eli Lilly to buy Verve Therapeutics for $1.3B - breakingthenews.net
2.79%
자본화:
|
볼륨(24시간):